XML 76 R57.htm IDEA: XBRL DOCUMENT v3.24.3
Option Agreements (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 8 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Feb. 06, 2024
Dec. 31, 2023
Mar. 31, 2024
Sep. 30, 2024
Sep. 30, 2024
Option Agreements [Line Items]              
Initiation fee             $ 800
Development costs, percentage             50.00%
Research and development expenses [1]           $ 25,691 $ 49,557
Accounts payable and other current liabilities           3,800 3,800
Development costs       $ 3,300      
Research initiation fee           800 800
Expenses           13,400 33,800
Clinical Development Milestones [Member]              
Option Agreements [Line Items]              
Non-refundable milestone payments     $ 12,000   $ 12,000    
Certain Regulatory Milestones [Member]              
Option Agreements [Line Items]              
Non-refundable milestone payments     $ 10,000   $ 10,000    
Related Party [Member]              
Option Agreements [Line Items]              
Accounts payable and other current liabilities           2,300 2,300
Research and Development Expense [Member]              
Option Agreements [Line Items]              
Research and development expenses           3,800 6,600
Research and Development Expense [Member] | ORKA-001 [Member]              
Option Agreements [Line Items]              
Milestone payment           1,500  
Research and Development Expenses [Member]              
Option Agreements [Line Items]              
Research and development expenses           $ 800 $ 13,200
Forecast [Member]              
Option Agreements [Line Items]              
Percentage of warrant purchase 1.00%            
Forecast [Member] | ORKA-002 [Member]              
Option Agreements [Line Items]              
Percentage of warrant purchase   1.00%          
[1] Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024